The Art of Licensing About Helsinn • Board of Directors and Top Management• Contacts• News 200820092010 Our locations • Switzerland• Ireland• USA Helsinn's recent history The Art of Development Building pharmaceuticalsOur R&D The Art of Access Making pharmaceuticals availableOur products • Cancer Supportive Care PalonosetronGelclairNetupitantAnamorelinZP1846 • Pain and Inflammation NimesulideOxaprozinRapid Absorption Platform • Gastroenterology PalonosetronKlean-Prep IpamorelinST-1141 • Areas under development UrologyThe Ghrelin Family The Art of Manufacturing High standard technologiesHelsinn Advanced Synthesis SA, BiascaHelsinn Birex Pharmaceuticals Ltd, Dublin The Art of Partnership Shaping alliances • Our partners Home > The Art of Access > Our products > Cancer Supportive Care > Netupitant Netupitant Netupitant is a potent and selective NK-1 receptor antagonist. It is under development for the prevention of chemotherapy-induced nausea and vomiting (CINV). Development status: Phase 3. Copyright © Helsinn Group - Legal Statement Last Update: 01.09.2010 About Helsinn Our Products Our Partners